Fecal calprotectin as predictor of relapse in patients with inflammatory bowel disease under maintenance infliximab therapy

Journal of Clinical Gastroenterology

Volumn 50, Issue 2, 2016, Pages 147-151

  Ferreiro Iglesias, Rocio ^a   Acosta, Manuel Barreiro De ^a   Santiago, Manuel Otero ^a   Gonzalez, Aurelio Lorenzo ^a   De La Peñ, Carmen Alonso ^a   Estevez, Alfonso J Benitez ^a   Dominguez Muño, Juan Enrique ^a  

^a University Hospital of Santiago de Compostela   (Spain)

Author keywords

Calprotectin; Crohn's disease; Inflammatory bowel disease; Infliximab; Ulcerative colitis

Indexed keywords

CALGRANULIN; INFLIXIMAB; ANTIINFLAMMATORY AGENT; BIOLOGICAL MARKER; GASTROINTESTINAL AGENT;

ADULT; AGED; ARTICLE; CLINICAL EXAMINATION; CLINICAL TRIAL; COHORT ANALYSIS; CROHN DISEASE; CROSS-SECTIONAL STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE EXACERBATION; FECAL CALGRANULIN RAPID TEST; FECES ANALYSIS; FECES LEVEL; FEMALE; HUMAN; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RAPID TEST; RECURRENT DISEASE; REMISSION; SENSITIVITY AND SPECIFICITY; ULCERATIVE COLITIS; ADOLESCENT; AREA UNDER THE CURVE; CHEMISTRY; COLITIS, ULCERATIVE; FECES; METABOLISM; MIDDLE AGED; RECEIVER OPERATING CHARACTERISTIC; RISK FACTOR; TIME FACTOR; TREATMENT OUTCOME; UPREGULATION; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTI-INFLAMMATORY AGENTS; AREA UNDER CURVE; BIOMARKERS; COLITIS, ULCERATIVE; CROHN DISEASE; CROSS-SECTIONAL STUDIES; FECES; FEMALE; GASTROINTESTINAL AGENTS; HUMANS; INFLIXIMAB; LEUKOCYTE L1 ANTIGEN COMPLEX; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; RECURRENCE; REMISSION INDUCTION; RISK FACTORS; ROC CURVE; TIME FACTORS; TREATMENT OUTCOME; UP-REGULATION; YOUNG ADULT;

EID: 84955326763     PISSN: 01920790     EISSN: 15392031     Source Type: Journal    
DOI: 10.1097/MCG.0000000000000312     Document Type: Article

References (40)

1. Vermeire S, Van Assche G, Rutgeerts P. Laboratory markers in IBD: useful, magic, or unnecessary toys? Gut. 2006;55:426-431.
2. Gisbert JP, Gonzalez Lama Y, Mate J. Role of biological markers in inflammatory bowel disease. Gastroenterol Hepatol. 2007;30:117-129.
3. Abraham BP, Kane S. Fecal markers: calprotectin and lactoferrin. Gastroenterol Clin North Am. 2012;41:483-495.
4. Poullis A, Foster R, Northfield TC, et al. Review article: faecal markers in the assessment of activity in inflammatory bowel disease. Aliment Pharmacol Ther. 2002;16:675-681.
5. Vieira A, Fang CB, Rolim EG, et al. Inflammatory bowel disease activity assessed by fecal calprotectin and lactoferrin: correlation with laboratory parameters, clinical, endoscopic and histological indexes. BCM Res Notes. 2009;2:221.
6. Tibble JA, Sigthorsson G, Foster R, et al. Use of surrogate markers of inflammation and Rome criteria to distinguish organic from nonorganic intestinal disease. Gastroenterology. 2002;123:450-460.
7. Baert F, Moortgat L, Van Assche G, et al. Mucosal healing predicts sustained clinical remission in patients with early stage Crohn's disease. Gastroenterology. 2010;138:463-468.
8. Colombel JF, Rutgeerts P, Reinisch W, et al. Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis. Gastroenterology. 2011;141:1194-1201.
9. Vermeire S, Van Assche G, Rutgeerts P. C-reactive protein as a marker for inflammatory bowel disease. Inflamm Bowel Dis. 2004;10:661-665.
10. Henriksen M, Jahnsen J, Lygren I, et al. C-reactive protein: a predictive factor and marker of inflammation in inflammatory bowel disease. Results from a prospective longitudinal study. Gut. 2008;57:1518-1523.
11. Johne B, Fagerhol MK, Lyberg T, et al. Functional and clinical aspects of the myelomonocyte protein calprotectin. Mol Pathol. 1997;50:113-123.
12. Roseth AG, Fagerhol MK, Aadland E, et al. Assessment of the neutrophil dominating protein calprotectin in feces. A methodologic study. Scand J Gastroenterol. 1992;27:793-798.
13. Konikoff MR, Denson LA. Role of fecal calprotectin as a biomarker of intestinal inflammation in inflammatory bowel disease. Inflamm Bowel Dis. 2006;12:524-534.
14. Hoff G, Grotmol T, Thiis-Evensen E, et al. Testing for faecal calprotectin (PhiCal) in the Norwegian Colorectal Cancer Prevention trial on flexible sigmoidoscopy screening: comparison with an immunochemical test for occult blood (FlexSure OBT). Gut. 2004;53:1329-1333.
15. Limburg PJ, Devens ME, Harrington JJ, et al. Prospective evaluation of fecal calprotectin as a screening biomarker for colorectal neoplasia. Am J Gastroenterol. 2003;98:2299-2305.
16. Tibble JA, Sigthorsson G, Foster R, et al. High prevalence of NSAID enteropathy as shown by a simple faecal test. Gut. 1999;45:362-366.
17. Poullis A, Foster R, Shetty A, et al. Bowel inflammation as measured by fecal calprotectin: a link between lifestyle factors and colorectal cancer risk. Cancer Epidemiol Biomarkers Prev. 2004;13:279-284.
18. Ertekin V, Selimoglu MA, Turgut A, et al. Fecal calprotectin concentration in celiac disease. J Clin Gastroenterol. 2010;44:544-546.
19. Costa F, Mumolo MG, Ceccarelli L, et al. Calprotectin is a stronger predictive marker of relapse in ulcerative colitis than in Crohn's disease. Gut. 2005;54:364-368.
20. D'Inca R, Dal Pont E, Di Leo V, et al. Can calprotectin predict relapse risk in inflammatory bowel disease? Am J Gastro-enterol. 2008;103:2007-2014.
21. Walkiewicz D, Werlin SL, Fish D, et al. Fecal calprotectin is useful in predicting disease relapse in pediatric inflammatory bowel disease. Inflamm Bowel Dis. 2008;14:669-673.
22. Gisbert JP, Bermejo F, Perez-Calle JL, et al. Fecal calprotectin and lactoferrin for the prediction of inflammatory bowel disease. Inflamm Bowel Dis. 2009;15:1190-1198.
23. Garcia-Sanchez V, Iglesias-Flores E, Gonzalez R, et al. Does fecal calprotectin predict relapse in patients with Crohn's disease and ulcerative colitis? J Crohns Colitis. 2010;4:144-152.
24. Sipponen T, Kolho KL. Faecal calprotectin in children with clinically quiescent inflammatory bowel disease. Scand J Gastroenterol. 2010;45:872-877.
25. Van Rheenen PF. Role of fecal calprotectin testing to predict relapse in teenagers with inflammatory bowel disease who report full disease control. Inflamm Bowel Dis. 2012;18: 2018-2025.
26. Laharie D, Mesli S, El Hajbi F, et al. Prediction of Crohn's disease relapse with faecal calprotectin in Infliximab responders: a prospective study. Aliment Pharmacol Ther. 2011;34:462-469.
27. Wassell J, Wallage M, Brewer E. Evaluation of the Quantum Blue rapid test for faecal calprotectin. Ann Clin Biochem. 2012;49:55-58.
28. Ton H, Brandsnes O, Dale S, et al. Improved assay for fecal calprotectin. Clin Chim Acta. 2000;292:41-54.
29. Tibble J, Teahon K, Thjodleifsson B, et al. A simple method for assessing intestinal inflammation in Crohn's disease. Gut. 2000;47:506-513.
30. Dolwani S, Metzner M, Wassell JJ, et al. Diagnostic accuracy of faecal calprotectin estimation in prediction of abnormal small bowel radiology. Aliment Pharmacol Ther. 2004;20: 615-621.
31. Molander P, af Bjorkesten CG, Mustonen H, et al. Fecal calprotectin concentration predicts outcome inflammatory bowel disease after induction therapy with TNFa blocking agents. Inflamm Bowel Dis. 2012;18:2011-2017.
32. Lonkvist MH, Theodorsson E, Holst M, et al. Blood chemistry markers for evaluation of inflammatory activity in Crohn's disease during Infliximab therapy. Scand J Gastroenterol. 2011;46:420-427.
33. Ho GT, Lee HM, Brydon G, et al. Fecal calprotectin predicts the clinical course of acute severe ulcerative colitis. Am J Gastroenterol. 2009;104:673-678.
34. Mao R, Xiao YL, Gao X, et al. Fecal calprotectin in predicting relapse of inflammatory bowel diseases: a meta-analysis of prospective studies. Inflamm Bowel Dis. 2012;18:1894-1899.
35. Vos M, Louis E, Jahnsen J, et al. Consecutive fecal calprotectin measurements to predict relapse in patients with ulcerative colitis receiving infliximab maintenance therapy. Inflamm Bowel Dis. 2013;19:2111-2117.
36. Lasson A, Simren M, Stotzer PO, et al. Fecal calprotectin levels predict the clinical course in patients with new onset of ulcerative colitis. Inflamm Bowel Dis. 2013;19:576-581.
37. Coorevits L, Baert FJ, Vanpoucke HJ. Faecal calprotectin: comparative study of the Quantum Blue rapid test and an established ELISA method. Clin Chem Lab Med. 2013; 51:825-831.
38. Sydora MJ, Sydora BC, Fedorak RN. Validation of a point-of-care desk top device to quantitate fecal calprotectin and distinguish inflammatory bowel disease from irritable bowel syndrome. J Crohns Colitis. 2012;6:207-214.
39. Hessels J, Douw J, Yildrim DD, et al. Evaluation of prevent ID and Quantum Blue rapid tests for fecal calprotectin. Clin Chem Lab Med. 2012;50:1079-1082.
40. Oyaert M, Trouve C, Baert F, et al. Comparison of two immunoassays for measurement of faecal calprotectin in detection of inflammatory bowel disease: (pre)-analytical and diagnostic performance characteristics. Clin Chem Lab Med. 2014;52:391-397.